Many providers will prescribe ursodeoxycholic acid. The most recent trial, PITCHES, did not show an overall beneficial effect, but some researchers believe that it may still be useful to offer ursodeoxycholic acid to women whose bile acids are > 40 μmol/litre. While there is no cure for<unk> , and no way to guarantee a successful outcome, studies have shown a slightly better fetal and maternal outcome from administration of ursodeoxycholic acid, whereas cholestyramine appears to only relieve itching. There is no evidence that giving oral water-soluble Vitamin K may help to avoid the risk of hemorrhage at delivery. However, experts in<unk>  will prescribe this if the woman reports pale stools, has very severe<unk>  (bile acids > 100 μmol/litre) or has a known clotting problem. Delivery from 34 weeks may be important to reduce the risk of stillbirth, as a recent study identified the level of bile acids at which stillbirth risk rises. This research, published in The Lancet, also suggests that around 90% of women with<unk>  could wait until 39 weeks of<unk>  to be induced. However, this relies on regular bile acid testing with rapid return of results.
Intrahepatic cholestasis of pregnancy
Neonatal cholestasis
Congenital hepatic fibrosis
Progressive familial intrahepatic cholestasis
Alcoholic hepatitis
Autoimmune hepatitis
Polycystic liver disease
Ischemic hepatitis